Ogawa A, Fukuta Y, Nakajima T, Kanno S M, Obara A, Nakamura K, Mizuki H, Takeda Y, Satoh M
First Department of Oral and Maxillofacial Surgery, School of Dentistry, Iwate Medical University, 1-3-27 Chuo-dori, Morioka 020-8505, Japan.
Oral Oncol. 2004 Sep;40(8):793-7. doi: 10.1016/j.oraloncology.2004.01.008.
The biologic behavior of and optimal treatment for oral verrucous carcinoma (VC) remain controversial. We analyzed the clinicopathological characteristics of 12 patients with oral VC. Immunohistochemical techniques were used to evaluate p53 protein, CD44 variant 9, and proliferating cell nucleus antigen. The TNM classification (UICC, 1997) was T1 in 1 patient, T2 in 3, T3 in 4, and T4 in 4. All patients were classified as N0M0. Four patients were treated by surgery alone and 8 by surgery after chemotherapy, radiotherapy, or both. After surgery, two patients had primary recurrence of disease. Immunohistochemically, the proliferative activity of tumor cells as evaluated by proliferating cell nuclear antigen labeling index and p53 protein expression was similar in VC and well-differentiated squamous cell carcinoma. However, CD44 varient 9 expression was positive in 8 of 10 VC, suggesting that oral VC is associated with a low risk of lymph node metastasis. Positive CD44 variant 9 expression by most oral VCs, indicating a low risk of cervical lymph node metastasis, suggests that most cases can be controlled by surgical intervention.
口腔疣状癌(VC)的生物学行为及最佳治疗方法仍存在争议。我们分析了12例口腔VC患者的临床病理特征。采用免疫组织化学技术评估p53蛋白、CD44变异体9和增殖细胞核抗原。根据TNM分类(UICC,1997),1例为T1,3例为T2,4例为T3,4例为T4。所有患者均分类为N0M0。4例患者仅接受手术治疗,8例在化疗、放疗或两者联合治疗后接受手术。术后,2例患者出现疾病原发复发。免疫组织化学结果显示,通过增殖细胞核抗原标记指数评估的肿瘤细胞增殖活性及p53蛋白表达在VC和高分化鳞状细胞癌中相似。然而,10例VC中有8例CD44变异体9表达呈阳性,提示口腔VC发生淋巴结转移的风险较低。大多数口腔VC的CD44变异体9表达阳性,表明颈部淋巴结转移风险较低,提示大多数病例可通过手术干预得到控制。